Tracking outcomes of chronic EBV infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study enrolls immunocompetent individuals with a high load of Epstein-Barr virus (EBV) DNA in their blood to monitor the natural history of chronic EBV infection. Participants will be followed up through interviews to assess the association between high EBV load and the development of hematological malignancies. The study also aims to investigate the genetic mechanisms behind immune escape and tumorigenesis related to chronic EBV infection. The primary outcomes include various types of hematological malignancies and chronic active EBV disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. immunocompetent subjects who was found to have high EBV-DNA load （\>1×103 copies/ml）in peripheral blood during the physical examination
2. Willing to be followed up by telephone or face-to-face interview

Exclusion Criteria:

1. Subjects with defined immunodeficiency
2. Subjects who have taken or are going to take immunosuppressive drugs.
3. Subjects Diagnosed a validated hematopathy
4. Subjects diagnosis as precancerous lesion or malignant tumor and the life expectancy is less than 1 year.
5. psychological illness which does not allow subjects to understand the study and participate following his own free will
6. Pregnant woman
7. no written informed consent

Where it's running

• Tongji hospital, Tongji medical collage of HUST
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Jin Huang, PhD.and MD.
• Email: hj20130318@163.com
• Phone: 86-15926444318

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Virus-specific T cells for kids after stem cell transplant

  This trial tests whether giving virus-specific T cells can safely help children with CMV, EBV, or BKV infections after a stem cell transplant.

  Recruiting LucasBio · Seoul · NCT07685457

• Multi-Virus Specific T cells for antiviral-resistant CMV, BKV, or EBV after cancer therapy or stem cell transplant

  This trial tests LB-DTK-MV cells to see if they safely reduce CMV, BKV, or EBV in patients who have antiviral-resistant infections after cancer treatment or stem cell transplant.

  Recruiting Phase 1/2 LucasBio · Seoul · NCT07670468

• Valacyclovir versus valganciclovir to prevent CMV and EBV after kidney transplant

  This test checks whether valacyclovir works as well as valganciclovir to prevent CMV and EBV in people who recently had a kidney transplant.

  Recruiting National Taiwan University Hospital · Taipei · NCT07294547

• Using EBV-TCR-T cells to treat EBV-related conditions

  This study is testing a new treatment using special immune cells to see if it can help people with serious conditions related to the Epstein-Barr virus.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT06135922

• T-cell therapy for viral infections after stem cell transplant

  This study is testing whether giving special T-cells that target specific viruses can help patients who have had a stem cell transplant and are struggling with tough viral infections.

  Recruiting at 33 sites Phase 3 University Hospital Freiburg · Brussels and 32 other locations · NCT04832607

• Evaluating 2LEBV® and 2LXFS® for fatigue in Epstein-Barr Virus patients

  This study is testing two new medications to see if they can help people aged 12 and older who have been feeling very tired due to Epstein-Barr Virus infections.

  Recruiting at 7 sites Phase 4 Labo'Life · Heule, Kortrijk and 7 other locations · NCT04308278

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.